&lt;p&gt;Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study&lt;/p&gt;

Yan, Jun; Man, Zhongsong; Lü, Qian; Ma, Kui

doi:10.2147/cmar.s237635

Cited by 4 publications

(1 citation statement)

References 32 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its high incidence of late diagnosis and rapid malignant progression, HCC remains a sigini cant global medical challenge with poor prognosis and high mortality rates 20 . Clock components have been implicated in the pathophysiology of various liver conditions, ranging from nonalcoholic fatty liver disease to HCC 21 .…”

Section: Discussionmentioning

confidence: 99%

PER1 enhances vascular normalization in hepatocellular carcinoma facilitating HIF-1α nuclear translocation

Zhang,

Fan,

Zhou

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Blood vessels play a significant role in the pathogenesis of hepatocellular carcinoma (HCC). Emerging evidence suggests that dysregulation of the circadian clock gene, period 1 (PER1), is closely associated with HCC tumorigenesis. However, it remains unknown whether PER1 regulate the angiogenesis in HCC. Methods: The Cancer Genome Atlas data was utilized for bioinformatics analysis to evaluate the potential clinical significance of PER1. Western Blot (WB) was employed to detect expression of PER1 in tumors and adjacent tissues. Subcutaneous xenograft models were used to investigate the biological function of PER1. Hematoxylin and eosin staining, immunohistochemical analysis, WB, RT-qPCR, and co-immunoprecipitation techniques were employed to elucidate the underlying mechanism of PER1. Results: The expression of PER1 was significantly downregulated and exhibited a positive correlation with favorable clinicopathological characteristics in HCC patients. Overexpression of PER1 led to decreased cell proliferation and contributed to the maintenance of vascular normalization in nude mice. Conversely, silencing of PER1 resulted in the opposite effect. Mechanistically, PER1 orchestrated the balance between proangiogenic and antiangiogenic factors by binding to HIF-1α, thereby promoting malignant tumor progression. Conclusion: Our findings demonstrated that the PER1/HIF-1α signaling axis plays a critical role in promoting vascular normalization in HCC by effectively balancing proangiogenic and antiangiogenic factors.

show abstract

Section: Discussionmentioning

confidence: 99%

PER1 enhances vascular normalization in hepatocellular carcinoma facilitating HIF-1α nuclear translocation

Zhang,

Fan,

Zhou

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas

et al. 2022

View full text Add to dashboard Cite

Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress

Shannon¹,

Ruff²,

Pawlik³

2022

JHC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a primary liver tumor that typically occurs in the setting of chronic liver disease/cirrhosis. Treatment modalities for HCC have evolved and given the variety of treatment options, a multi-disciplinary approach requiring input from surgical, medical, and radiation oncology, hepatology, and interventional radiology is necessary. Multiple advances have been made over the last decade regarding treatment of HCC, especially advanced disease. Resection and transplantation remain as cornerstone curative-intent treatment options. For patients who are not candidates for curative-intent therapy, exciting progress has been made in molecular and cellular approaches to systemic therapy for HCC including immunotherapies and tyrosine kinase inhibitors. Although the prognosis for advanced HCC remains poor, the armamentarium of therapies has increased, and valuable years of life can be gained with these therapies. While the main therapeutic modality for early-stage disease remains resection, multimodal immunotherapy has emerged as first-line treatment for advanced disease. We herein review different clinical and molecular treatment modalities related to the treatment of HCC, as well as provide insights into future directions for HCC treatment. We highlight how research and progress are needed to move into a new era of molecular and cellular treatments.

show abstract

<p>Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study</p>

Cited by 4 publications

References 32 publications

PER1 enhances vascular normalization in hepatocellular carcinoma facilitating HIF-1α nuclear translocation

PER1 enhances vascular normalization in hepatocellular carcinoma facilitating HIF-1α nuclear translocation

Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas

Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress

Contact Info

Product

Resources

About